Axsome Therapeutics (AXSM) Total Liabilities (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Total Liabilities data on file, last reported at $659.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 21.26% year-over-year to $659.0 million; the trailing twelve-month figure through Mar 2026 stood at $659.0 million (up 21.26% YoY), and the FY2025 full-year result was $601.5 million, up 17.6% from the prior year.
• Total Liabilities advanced to $659.0 million in Q1 2026, from $601.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $659.0 million in Q1 2026 to a low of $73.9 million in Q1 2022.
• A 5-year average of $398.5 million and a median of $401.7 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities advanced 4.6% in 2022 and soared 275.52% in 2023, its largest moves.
• Tracing AXSM's Total Liabilities over 5 years: stood at $221.9 million in 2022, then soared by 79.01% to $397.3 million in 2023, then gained by 28.75% to $511.5 million in 2024, then gained by 17.6% to $601.5 million in 2025, then rose by 9.56% to $659.0 million in 2026.
• Business Quant data shows AXSM's Total Liabilities at $659.0 million in Q1 2026, $601.5 million in Q4 2025, and $595.5 million in Q3 2025.